AnaptysBio, Inc. (ANAB) – What Are Analysts Saying About This Stock?

AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $77.79.

ANAB has been the subject of several research analyst reports. Wall Street Zen lowered shares of AnaptysBio from a “buy” rating to a “hold” rating in a research report on Sunday, October 4th. Scotiabank downgraded AnaptysBio to a “hold” rating and set a $70.00 target price for the company. in a research report on Tuesday, August 25th. JPMorgan Chase & Co. decreased their price target on shares of AnaptysBio from $70.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 30th. TD Cowen decreased their target price on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, August 25th. Finally, HC Wainwright restated a “buy” rating and set a $95.00 target price on shares of AnaptysBio in a report on Tuesday, September 22nd.

AnaptysBio Stock Up 1.3%

NASDAQ ANAB opened at $48.73 on Friday. The firm has a market cap of $1.46 billion, a P/E ratio of 9.07 and a beta of 0.76. The company’s 50 day moving average is $52.67 and its 200-day moving average is $57.14. AnaptysBio has a 12-month low of $20.18 and a 12-month high of $72.36.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $5.57. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%. The company had revenue of $27.49 million during the quarter, compared to analysts’ expectations of $14.06 million. During the same period in the previous year, the business earned ($1.30) earnings per share. Equities analysts expect that AnaptysBio will post -1.30 EPS for the current year.

Insider Transactions at AnaptysBio

In related news, Director Hollings Renton sold 5,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $49.87, for a total value of $249,350.00. Following the completion of the sale, the director owned 10,995 shares of the company’s stock, valued at $548,320.65. This trade represents a 31.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 31.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC grew its stake in shares of AnaptysBio by 847.8% during the 3rd quarter. Sterling Capital Management LLC now owns 654 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 585 shares during the period. Kings Path Partners LLC bought a new position in shares of AnaptysBio during the 3rd quarter valued at approximately $188,000. Robeco Institutional Asset Management B.V. purchased a new stake in AnaptysBio in the 3rd quarter worth approximately $852,000. State of Alaska Department of Revenue purchased a new stake in AnaptysBio in the 3rd quarter worth approximately $85,000. Finally, Farther Finance Advisors LLC boosted its position in shares of AnaptysBio by 2,440.0% in the third quarter. Farther Finance Advisors LLC now owns 10,033 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 9,638 shares during the period.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated diseases. The company uses its proprietary antibody discovery and engineering platform to identify therapeutics designed to modulate immune-system pathways involved in inflammation and autoimmune disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 immune checkpoint pathway, and imsidolimab, an investigational antibody targeting the interleukin-36 receptor.